Omeros (OMER) Invested Capital (2010 - 2026)
Omeros (OMER) posted Invested Capital of $1.2 million for Q4 2025, down 95.45% sequentially from $26.9 million in Q1 2025, and down 37.94% YoY from $2.0 million in Q4 2024.
Analysis
Omeros (OMER) Invested Capital (2010 - 2026) Analysis & Trends
Omeros has reported Invested Capital for 12 years, with the latest figure at $1.2 million in Q4 2025.
- Quarterly Invested Capital fell 37.94% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 95.76% YoY) and the FY2025 annual result came in at $1.2 million, down 37.94% from the prior year.
- Invested Capital declined to $1.2 million in Q4 2025 per OMER's latest filing, from $26.9 million in the prior quarter.
- Over five years, Invested Capital peaked at $94.9 million in Q3 2023 and troughed at $1.2 million in Q4 2025.
- A 4-year average of $51.2 million and a median of $60.7 million in 2022 frame the typical range for Invested Capital.
- The sharpest annual moves came in 2023 and 2024: Invested Capital sank 98.63% in 2023, then jumped 53.14% in 2024.
- Over 4 years, Invested Capital stood at $94.4 million in 2022, then tumbled by 98.63% to $1.3 million in 2023, then surged by 53.14% to $2.0 million in 2024, then slumped by 37.94% to $1.2 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods registered $1.2 million, $26.9 million, and $2.0 million for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Omeros | 1.37 Bn | 1.37 Bn | 27.73 Mn | -9.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.32 Mn |
| Mar 31, 2026 | -10.52 Mn |
| Dec 31, 2025 | -52.80 Mn |
| Sep 30, 2025 | -115.96 Mn |
| Jun 30, 2025 | -124.36 Mn |
| Mar 31, 2025 | -98.06 Mn |
| Dec 31, 2024 | -64.43 Mn |
| Sep 30, 2024 | -57.14 Mn |
| Jun 30, 2024 | -27.71 Mn |
| Mar 31, 2024 | 142.14 Mn |
| Dec 31, 2023 | 188.17 Mn |
| Sep 30, 2023 | 302.79 Mn |
| Jun 30, 2023 | 336.76 Mn |
| Mar 31, 2023 | 370.70 Mn |
| Dec 31, 2022 | 400.97 Mn |
| Sep 30, 2022 | 268.51 Mn |
| Jun 30, 2022 | 281.66 Mn |
| Mar 31, 2022 | 308.98 Mn |
| Dec 31, 2021 | 337.24 Mn |
| Sep 30, 2021 | 50.32 Mn |